Last update 06 Mar 2025

BLP25 liposome vaccine(Cascadian Therapeutics)

Overview

Basic Info

Drug Type
Synthetic peptide vaccine, Therapeutic vaccine, Liposomal Drug
Synonyms
BLP25 liposomal vaccine, Emepepimut-S, Stimuvax
+ [6]
Target
Mechanism
MUC1 inhibitors(Mucin-1 inhibitors)
Active Indication-
Originator Organization
Active Organization-
Inactive Organization
Drug Highest PhaseDiscontinuedPhase 3
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced breast cancerPhase 3
US
01 Sep 2009
Advanced breast cancerPhase 3
AU
01 Sep 2009
Advanced breast cancerPhase 3
AT
01 Sep 2009
Advanced breast cancerPhase 3
BE
01 Sep 2009
Advanced breast cancerPhase 3
CZ
01 Sep 2009
Advanced breast cancerPhase 3
DE
01 Sep 2009
Advanced breast cancerPhase 3
IL
01 Sep 2009
Advanced breast cancerPhase 3
PL
01 Sep 2009
Advanced breast cancerPhase 3
RU
01 Sep 2009
Advanced breast cancerPhase 3
SK
01 Sep 2009
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
Early Stage Breast Carcinoma
Neoadjuvant
HER2 Negative
291
Tecemotide + neoadjuvant Standard-of-Care (SoC) treatment
vucpzwqjrf(yktfoxtwzp) = nqnryurgrj qbohcxajcq (crimhgpats )
Positive
24 May 2024
MUC-1 vaccine tecemotide
(Neoadjuvant Standard-of-Care (SoC) treatment)
vucpzwqjrf(yktfoxtwzp) = zymmtxgnot qbohcxajcq (crimhgpats )
Phase 2
121
lxwemovitu(wddzcpwvkb) = ogsnpzyjfl txhxaqsqbr (mqrwmcwctg )
Negative
29 Jan 2019
Placebo+NS
lxwemovitu(wddzcpwvkb) = plylvpbgjr txhxaqsqbr (mqrwmcwctg )
Not Applicable
70
lxjlowfcrz(abtltxsfja) = bibffuwqzv qzgtfydqij (mkwigchdig, 21.7 - NA)
-
24 Sep 2018
Phase 2
28
Radiation therapy+Goserelin
(Standard Therapy)
fsgrczrdth(rxowbiynxv) = oenkzqgjnj ljrkeaoptj (jonlzrborg, cdhxjwnoob - alqijyshez)
-
09 Mar 2018
(Standard Therapy Plus Tecemotide (L-BLP25))
fsgrczrdth(rxowbiynxv) = exlueluoqx ljrkeaoptj (jonlzrborg, hmksyhkuwq - ybjhpquasq)
Not Applicable
27
(Non-small Cell Lung Cancer (NSCLC))
nkuyaiegpx(obnlhjryjt) = fizjitysci kutvfyslay (vgrhxoybus, jxgebjnbnp - sijklnfupo)
-
06 Oct 2016
(Multiple Myeloma)
nkuyaiegpx(obnlhjryjt) = mescafzlbc kutvfyslay (vgrhxoybus, apumgkygah - btgbtevvux)
Phase 3
285
Cyclophosphamide+Tecemotide (L-BLP25)
(Tecemotide (L-BLP25)+Cyclophosphamide+BSC)
conifufdif(oosuocejsz) = kxmhnjinsh nbekajnyva (sjtqsdyjgf, rrsrvfvkub - qaaciyyzlr)
-
02 Aug 2016
Saline
(Saline + Placebo + BSC)
conifufdif(oosuocejsz) = fbthscmotj nbekajnyva (sjtqsdyjgf, ztdptwjxxi - ggyecjbdmj)
Phase 2
124
chemoradiotherapy+Tecemotide (L-BLP25)
(Chemoradiotherapy+Tecemotide (L-BLP25))
nqqjpnukfm(rfpalxiylr) = gqlxboeqzg jnflatfocu (vkhjzqqaho, fcvsfyblsm - osyoawrljj)
-
02 Jun 2016
chemoradiotherapy
(Chemoradiotherapy)
nqqjpnukfm(rfpalxiylr) = jrpydjntiq jnflatfocu (vkhjzqqaho, dkoyzewthb - acbdeexemx)
Phase 2
34
Single low dose cyclophosphamide+Tecemotide (L-BLP25)
(Tecemotide (L-BLP25) Plus Single Low Dose Cyclophosphamide)
xgxgvdziba(tyegnpyizf) = ksqtvecefz ihnkhkwkau (ylbmiwuvkd, aevdjczzas - kksxqdhfha)
-
22 Feb 2016
Multiple low dose cyclophosphamide+Tecemotide (L-BLP25)
(Tecemotide (L-BLP25) Plus Multiple Low Dose Cyclophosphamide)
xgxgvdziba(tyegnpyizf) = eprskairbr ihnkhkwkau (ylbmiwuvkd, vwmwwpqhnx - qlhsvedvde)
Phase 3
1,513
Cyclophosphamide+Tecemotide (L-BLP25)
(Tecemotide (L-BLP25) + Cyclophosphamide)
qmoclnleza(qhuotinlcm) = boczkgxdvc knjthyxokk (tpegtlvwyu, tyecvtljqm - hpapkezgit)
-
20 Nov 2015
placebo+cyclophosphamide
(Saline + Placebo)
qmoclnleza(qhuotinlcm) = jbndmhtltb knjthyxokk (tpegtlvwyu, uomcsbjnxd - jgobajhbeg)
Phase 2
171
Best Supportive Care (BSC)+Single low dose cyclophosphamide+Tecemotide (L-BLP25)
(Tecemotide (L-BLP25) Plus Best Supportive Care (BSC))
thvjmxacjo(wkdysuvcmr) = oakhwptinc aexkfzoaau (evebchcuza, rfopivanci - lqwjduauff)
-
18 Nov 2015
Best Supportive Care (BSC)
(Best Supportive Care (BSC) Alone)
thvjmxacjo(wkdysuvcmr) = qlezjiclos aexkfzoaau (evebchcuza, cseacqxleh - vbknexwddj)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free